This article is more than 5 years old. Information may no longer be current.
Visual acuity gains seen in Vibrant study maintained beyond 24 weeks
Click Here to Manage Email Alerts
SAN DIEGO — At week 52 of the VIBRANT study, best corrected visual acuity letter score improved in a greater percentage of patients receiving intravitreal aflibercept injection than in patients undergoing laser treatment for branch retinal vein occlusion, according to a speaker here.
Peter Campochiaro, MD, delivered updated findings of the study at the American Society of Retina Specialists annual meeting. The VIBRANT study included 183 patients with center-involved macular edema secondary to branch retinal vein occlusion who were randomly assigned to undergo intravitreal injections with Eylea (aflibercept, Regeneron) or laser treatment.
“The primary endpoint shows that significantly more patients in the aflibercept group had three or more lines of improvement with respect to ETDRS letter score: 52%, roughly twice as many, vs. 26% in the laser group,” Campochiaro said.
The benefit was maintained in the aflibercept group after the original 24-week endpoint, with 57% of the aflibercept group having three or more lines of improvement at week 52.
In the extended study, patients received every-8-week dosing of aflibercept after 6 monthly injections.
Disclosure: Campochiaro is a consultant for Genentech, Alimera, Advanced Cell Technology, Aerpio Therapeutics, Applied Genetic Technologies, Gene Signal, KalaTherapeutics and Regeneron.